Comment prévenir 9 différents cancers et les vérrues génitales

Rapport publié

Le Canada est dans une position unique pour être un contributeur majeur à cet effort important. En 2019, un groupe d’experts a élaboré un rapport contenant 105 recommandations pour la mise en œuvre d’actions tant au Canada qu’à l’étranger pour atteindre les objectifs suivants:


  •          90% des filles entièrement vaccinées avec le vaccin contre le VPH à l’âge de 15 ans;
  •          90% des femmes dépistées avec un test de haute performance à 35 et 45 ans; et
  •          90% des femmes identifiées avec une maladie cervicale reçoivent un traitement.

Rapports et déclarations

  • Human Papillomavirus and Related Diseases in Canada. Summary Report 2015-03-20: Read Document
  • An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)†. Read Document


  • Healer of Cancer: The Power of the Mind, by Dr. Christian Boukaram: External Link
  • The HPV Vaccine Controversy, by Shobha S. Krishnan, M.D. External Link


  • Including males in Canadian human papillomavirus vaccination programs: a policy analysis.Read Document
  • Rebuttal: Do you approve of spending $300 million on HPV Vaccination?- Dr Marc Steben says yes.Read Document
  • Beliefs, behaviours and HPV vaccine: Correcting the myths and the misinformation Read Document
  • The Early Benefits of Human Papillomavirus Vaccination on Cervical Dysplasia and Anogenital Warts Read Document
  • Adverse events following immunization in Ontario’s female school-based HPV program Read Document
  • Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study Read Document
  • Are twenty human papillomavirus types causing cervical cancer? Read Document
  • Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes Read Document
  • Sex Differences Among College Students in Awareness of the HPV Vaccine and Vaccine Options Read Document
  • HPV vaccination: for women of all ages? Read Document
  • What is the responsibility of national government with respect to vaccination? Read Document
  • Financial Incentives for Increasing Uptake of HPV Vaccinations: A Randomized Controlled Trial Read Document
  • Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study Read Document
  • Indications for the HPV vaccine in adolescents: A review of the literature Read Document
  • The age of distribution of type-specific high-risk human papillomavirus incidence in two population-based screening trials Read Document
  • The Politics of HPV VAccination Advocacy: Effects of Source Expertise on Effectiveness of a Pro-Vaccine Message Read Document
  • Estimation of Geographic Variation in Human Papillomavirus Vaccine Uptake in Men and Women: An Online Survey Using Facebook Recruitment Read Document
  • Long-term Study of a Quadrivalent Human Papillomavirus Vaccine Read Document
  • Human Papillomavirus Vaccine Knowledge and Attitudes, Preventative Health Behaviors, and Medical Mistrust Among a Racially and Ethnically Diverse Sample of College Women Read Document
  • A risk for non-sexual transmission of human papillomavirus? Read Document
  • Immunisation against HPV in girls with intellectual disabilities Read Document
  • Implementation Science in Cancer Prevention and Control: A framework for research and programs in low and middle-income countries Read Document
  • Beta-Test Results for an HPV Information Web Site: Increasing HPV Vaccine Uptake in the United States Read Document
  • Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescent and young adults Read Document
  • Missed Opportunities for HPV Vaccination in Adolescent Girls: A Qualitative Study Read Document
  • Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study Read Document
  • Sex Is Like Jelly Beans: Educating Students on the Risks of Oral Sex Read Document
  • Primary care providers human papillomavirus vaccine recommendations for the medically underserved: A pilot study in U.S. Federally Qualified Health Centers Read Document
  • Early effects of human papillomavirus vaccination in Belgium Read Document
  • Co-infection with HPV types from the same species provides natural cross-protection from progression to cervical cancer Read Document
  • HPV Test Information. Read Document

Vaccin contre le VPH – Gardasil®

  • Product Monograph, Gardasil® [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine] Suspension for injection, Active Immunizing Agent: Read Document
  • Part III: Consumer Information, Gardasil® [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine]: Read Document

Vaccin contre le VPH – Gardasil9

  • Product Monograph, Gardasil® 9 [Human Papillomavirus 9-valent Vaccine, Recombinant] Suspension for injection, Active Immunizing Agent: Read Document
  • Part III: Consumer Information, Gardasil® 9 [Human Papillomavirus 9-valent Vaccine, Recombinant]: Read Document

Vaccin contre le VPH – Cervarix

  • Health Canada approves CERVARIX™, new GSK cervical cancer vaccine: Read Document
  • Product Monograph, Cervarix®[Human Papillomavirus vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted)] Suspension for injection, Active Immunizing Agent. ATC code: J07BM02: Read Document